Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine in treatment-resistant depression
NCT02401139Phase 1Completed
- Sponsor
- University of New South Wales
- Start
- Mar 2015
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in major depressive disorder (MDD) comparing Ketamine Arm with Placebo Arm (2 arms). Primary endpoint: Montgomery Asberg Depression Rating Scale at 4 weeks. Started Mar 2015; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02401139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02401139.